<DOC>
	<DOC>NCT00243243</DOC>
	<brief_summary>The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower the amount of blood lost during burn surgery.</brief_summary>
	<brief_title>Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn</brief_title>
	<detailed_description>To identify the clinical use for Factor VIIa in the operating room to reduce blood loss and blood transfusion , determine the Recombinant Factor VIIa (rFVIIa) pharmacokinetics in burned patients, determine if fFVIIa should be used to reduce peri-operative blood loss in patients undergoing excision greater than or equal to 20 percent of the total body surface area, determine the efficacy of the drug in burned patients undergoing excision of burn wounds.</detailed_description>
	<mesh_term>Burns</mesh_term>
	<criteria>Male or female Burn wounds 1865 years of age Scheduled excision of burn wound of at least 20 percent TBSA Age greater than 65 years History of blood coagulation disorders Taking anticoagulation medication Contraindication for heparin therapy Pregnant or nursing females Unstable angina MI within the last 6 months Recent of diagnosis of DVT, stroke within the last 6 months Renal failure requiring dialysis or creatinine clearance less than 25 ml/min Religious prohibition to blood transfusion Have received rFVIIa during current hospitalization Previous enrollment in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Burns</keyword>
</DOC>